Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep-Oct;22(5):375-379.
doi: 10.4103/1319-3767.191143.

Pigment epithelium-derived factor and matrix metalloproteinase-9 in liver cirrhosis

Joanna Kozlowska  1 , Tomasz Mikula  1 , Magdalena Suchacz  1 , Joanna Jabnonska  1 , Wojciech Stanczak  1 , Janusz Cianciara  1 , Alicja Wiercinska-Drapalo  1
Affiliations

Pigment epithelium-derived factor and matrix metalloproteinase-9 in liver cirrhosis

Joanna Kozlowska et al. Saudi J Gastroenterol. 2016 Sep-Oct.

Abstract

Background/aim: The aim of this study was to assess the role of serum pigment epithelium-derived factor (PEDF) and matrix metalloproteinase-9 (MMP-9) in progression of liver cirrhosis and development of hepatocellular carcinoma (HCC).

Patients and methods: Serum levels of PEDF and MMP-9 were tested in 212 patients with liver cirrhosis and in a control group of 30 healthy volunteers. HCC was diagnosed in 45 of the 212 patients studied (21%).

Results: Serum PEDF and MMP-9 were higher in the study group than that in the control group (P < 0.001). In patients with alcoholic or mixed (alcoholic and viral hepatitis-related) cirrhosis, serum PEDF was higher than that in other patients (13970.2 ± 13406.9 ng/ml vs. 8563.5 ± 9602.7 ng/ml, P = 0.008). In patients with viral hepatitis-related cirrhosis, significantly higher PEDF levels were recorded in those with HCC (13429.1 ± 12045.8) than that in patients without HCC (6660.1 ± 7927.1; P = 0.04). There was a trend for higher serum MMP-9 in patients with HCC (5778.7 ± 12426.6 vs. 1389.8 ± 1944.7 in those without HCC; P = 0.07). Significant negative correlation between serum MMP-9 and serum alpha-fetoprotein in patients with HCC was observed (r = -0.54; P = 0.04).

Conclusion: Serum PEDF and MMP-9 could be auxiliary markers in diagnosis of HCC, especially in patients with low alpha-fetoprotein level. Alcohol consumption can affect serum PEDF.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Serum PEDF in groups A, B, and C according to the Child-Pugh; P = NS
Figure 2
Figure 2
Serum MMP-9 in groups A, B, and C according to the Child-Pugh; P = NS
Figure 3
Figure 3
Serum PEDF depending on the alcoholic etiology of cirrhosis; P = 0.008. AC, alcoholic cirrhosis; non-AC, non-alcoholic cirrhosis.
Figure 4
Figure 4
Serum PEDF in patients with viral hepatitis-related cirrhosis, depending on the presence of HCC; P = 0.04
Figure 5
Figure 5
Serum MMP-9 in patients with cirrhosis, depending on the presence of HCC; P = 0.07
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, Zhang BC, et al. Screening for liver cancer: Results of a randomised controlled trial in Qidong, China. J Med Screen. 2003;10:204–9. - PubMed
    1. Paul SB, Gulati MS, Sreenivas V, Madan K, Gupta AK, Mukhopadhyay S, Acharya SK. Evaluating patients with cirrhosis for hepatocellular carcinoma: Value of clinical symptomatology, imaging and alpha-fetoprotein. Oncology. 2007;72(Suppl 1):117–23. - PubMed
    1. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology. 2011;53:1020–2. - PMC - PubMed
    1. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43. - PubMed
    1. World Health Organization. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. 2015. Mar, [Last accessed on August 08, 2016]. Available from: URL: http://www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/ - PubMed